Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma-Reference-Cited by-同舟云学术

Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma

Published:2022-08-25 Issue:12 Volume:107 Page:2961-2965
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Asher Samir,Kazantzi Aikaterini,Dekaj Fatjon,Steventon Luke,Khatun Aisha,Ainley Louise,McMillan Annabel,Rabin Neil,Wechalekar Ashu,Sive Jonathan,Kyriakou Charalampia,Papanikolaou Xenofon,Xu Ke,Mahmood Shameem,Wisniowski Brendan,Lee Lydia,Yong Kwee,Popat Rakesh

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference15 articles.

1. Cancer Research UK. Myeloma statistics. 2018.

2. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011; 183:25-35.

3. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012; 26(4):609-614.

4. National Cancer Intelligence Network and Cancer Research UK. Cancer incidence and survival by major ethnic group, England, 2002-2006.

5. Waxman AJ, Mink PJ, Devesa SS. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010; 116(25):5501-5506.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A framework for evaluating the diversity of clinical trials;Journal of Clinical Epidemiology;2024-05

2. A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers;Gynecologic Oncology;2024-05

3. “It’s not about the money, money” - Well, actually it is. Divergent views on drivers of early phase clinical trial participation among ethnically diverse potential trial participants in the United Kingdom: A Mixed Methods Study;2024-04-05

4. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11

5. Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action;BMJ Oncology;2023-11